Publications by authors named "Rodney A Bednar"

Claim this Profile
P
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist.
Rachel Garner, Shobha Gopalakrishnan, John A McCauley, Rodney A Bednar, Stanley L Gaul

Pharmacol Res Perspect· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Swati P Mercer, Anthony J Roecker, Susan Garson, Duane R Reiss, C Meacham Harrell, Rodney A Bednar

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Paul J Coleman, John D Schreier, Christopher D Cox, Michael J Breslin, David B Whitman, Rodney A Bednar

ChemMedChem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.
Mark E Layton, Michael J Kelly, Kevin J Rodzinak, Philip E Sanderson, Steven D Young, Rodney A Bednar

ACS Chem Neurosci· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.
Michael R Wood, Kathy M Schirripa, June J Kim, Rodney A Bednar, John F Fay

Bioorg Med Chem Lett· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Christopher D Cox, Michael J Breslin, David B Whitman, John D Schreier, Georgia B McGaughey, Rodney A Bednar

J Med Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, highly constrained CGRP receptor antagonists.
Craig A Stump, Ian M Bell, Rodney A Bednar, John F Fay, Steven N Gallicchio

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive allosteric interaction of structurally diverse T-type calcium channel antagonists.
Victor N Uebele, Cindy E Nuss, Steven V Fox, Susan L Garson, Razvan Cristescu, Rodney A Bednar

Cell Biochem Biophys· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.
Michael R Wood, Kathy M Schirripa, June J Kim, Amy G Quigley, Craig A Stump, Rodney A Bednar

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
Charles J McIntyre, John A McCauley, Bohumil Bednar, Rodney A Bednar, John W Butcher

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
Ian M Bell, Rodney A Bednar, Halea A Corcoran, John F Fay, Steven N Gallicchio

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
David B Whitman, Christopher D Cox, Michael J Breslin, Karen M Brashear, John D Schreier, Rodney A Bednar

ChemMedChem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of highly potent CGRP receptor antagonists.
Craig A Stump, Ian M Bell, Rodney A Bednar, Joseph G Bruno, John F Fay

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent benzimidazolone-based CGRP receptor antagonists.
Cory R Theberge, Rodney A Bednar, Ian M Bell, Halea A Corcoran, John F Fay

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proline bis-amides as potent dual orexin receptor antagonists.
Jeffrey M Bergman, Anthony J Roecker, Swati P Mercer, Rodney A Bednar, Duane R Reiss

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.
Michael R Wood, Kathy M Schirripa, June J Kim, Scott D Kuduk, Ronald K Chang, Rodney A Bednar

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
Kevin T Nguyen, Christopher F Claiborne, John A McCauley, Brian E Libby, David A Claremon, Rodney A Bednar, Bohumil Bednar

Bioorg Med Chem Lett· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Nigel J Liverton, Rodney A Bednar, Bohumil Bednar, John W Butcher, Christopher F Claiborne

J Med Chem· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.
Ian M Bell, Rodney A Bednar, John F Fay, Steven N Gallicchio, Jerome H Hochman

Bioorg Med Chem Lett· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro characterization of novel NR2B selective NMDA receptor antagonists.
Laszlo Kiss, Gong Cheng, Bohumil Bednar, Rodney A Bednar, Paul B Bennett

Neurochem Int· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
John A McCauley, Cory R Theberge, Joseph J Romano, Susan B Billings, Kenneth D Anderson, Rodney A Bednar, Bohumil Bednar

J Med Chem· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally efficacious NR2B-selective NMDA receptor antagonists.
Christopher F Claiborne, John A McCauley, Brian E Libby, Neil R Curtis, Helen J Diggle, Rodney A Bednar, Bohumil Bednar

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1).
Philippe G Nantermet, James C Barrow, George F Lundell, Janetta M Pellicore, Kenneth E Rittle, Rodney A Bednar

Bioorg Med Chem Lett· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis